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Abstract
Background: Laminin, a major basement membrane component that has direct contact with pericytes under
physiological conditions, actively regulates the proliferation and differentiation/fate determination of pericytes.
Recently, two types of pericytes (type I and type II) with different molecular markers and functions have been
identified in skeletal muscles. Whether laminin differentially regulates the proliferation and differentiation of these
two subpopulations remains unclear.
Methods: Wild-type and pericytic laminin-deficient mice under Nestin-GFP background were used to determine if
laminin differentially regulates the proliferation and differentiation of type I and type II pericytes. Specifically, type I
and type II pericytes were isolated from these mice, and their proliferation and differentiation were examined in
vitro. Moreover, in vivo studies were also performed.
Results: We demonstrate that, although laminin inhibits the proliferation of both type I and type II pericytes in
vitro, loss of laminin predominantly induces proliferation of type II pericytes in vivo. In addition, laminin negatively
regulates the adipogenic differentiation of type I pericytes and positively regulates the myogenic differentiation of
type II pericytes in vitro.
Conclusions: Laminin differentially regulates the proliferation and differentiation of type I and type II pericytes.
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Background
Satellite cells (postnatal muscle progenitor cells) are sand-
wiched between the basal lamina and myofiber plasma
membrane in skeletal muscles [1]. Unlike satellite cells,
various other cell populations, including fibro/adipogenic
progenitors (FAPs) [2, 3], PW1+/Pax7− interstitial cells
(PICs) [4], mesenchymal stem cells (MSCs) [5–7], fibro-
blasts [8], and pericytes [9, 10], are found in the interstitial
space of skeletal muscles. These populations are distinct
from each other in their marker expression and differenti-
ation abilities/functions. Specifically, FAPs are α7-integrin
−Sca-1+PDGFRα+, and produce both fibroblasts and adi-
pocytes [2, 3]. PICs are Sca-1MedCD34+PW1+Pax7− and
have myogenic potential [4]. MSCs express a wide range
of stem cell markers and are able to generate adipose,
bone, cartilage, and muscle [5–7, 11, 12]. Fibroblasts ex-
press ER-TR7, FSP1, and Tcf4, and are involved in tissue
fibrosis [8]. Pericytes (perivascular cells covering capillar-
ies in the vascular tree [13]) express a unique array of
markers, including PDGFRβ, NG2, CD146, and CD13
[13]. It should be noted, however, that none of these
markers are specific for pericytes since they are also
expressed by other cell types, and their expression in peri-
cytes is highly dependent on the developmental stages
[13]. Accumulating evidence suggests that pericytes are
multipotent cells. On one hand, pericytes are able to dif-
ferentiate into myogenic cells via myogenesis to repair
muscle injury [9, 10, 14–16]. On the other hand, pericytes
can also differentiate into adipocytes and/or fibroblasts
[14, 17–21], exacerbating muscle injury.
Recently, two subtypes (termed type I and type II) of
pericytes with different molecular markers and differenti-
ation abilities have been reported in skeletal muscles. Bio-
chemically, both type I and type II pericytes express
various classical pericyte markers, including PDGFRβ,
NG2, and CD146 [14, 22]. It is the expression of Nestin,
an intermediate filament protein, that differentiates these
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two subtypes of pericytes: type I (PDGFRβ+/NG2+/CD146
+ and Nestin−) and type II (PDGFRβ+/NG2+/CD146+ and
Nestin+) [14, 22, 23]. It is worth noting that “Nestin” here
refers to transgene Nestin-GFP from the Nestin-GFP mice
(see Methods), not endogenous Nestin. Since Nestin-GFP
cells express low levels of endogenous Nestin in bone
marrow [24], caution should be taken when using en-
dogenous Nestin to distinguish type I and type II peri-
cytes. Further studies conducted by Birbrair and
colleagues elegantly demonstrate that type I pericytes
differentiate into adipogenic and fibrogenic cells, con-
tributing to muscle degeneration, whereas type II
pericytes undergo myogenesis, promoting muscle re-
generation [14, 23, 25, 26]. These data suggest that
type I and type II pericytes are intrinsically different,
and have distinct differentiation capability and fate.
The molecular mechanisms underlying pericyte differ-
entiation and fate determination are not fully under-
stood. In a previous study, we identified laminin as a
critical regulator in the differentiation and fate determin-
ation of PDGFRβ+ pericytes [21]. Specifically, we found
that laminin negatively regulates their proliferation, in-
hibits their adipogenic differentiation, and is indispens-
able for their myogenic differentiation [21]. Whether
laminin differentially regulates the differentiation and
fate determination of type I and type II pericytes, how-
ever, remains unclear. Using the Nestin-GFP and lam-
inin conditional knockout mice, we report here that
laminin inhibits the proliferation of both type I and type
II pericytes in vitro. Type II pericytes, however, predom-
inantly proliferate in vivo upon loss of laminin. In
addition, laminin prevents adipogenic differentiation of
type I pericytes, but is required for myogenic differenti-
ation of type II pericytes. These data suggest that lam-
inin inhibits the proliferation of type II pericytes, and
has anti-adipogenic and pro-myogenic effects on type I
and type II pericytes, respectively.
Methods
Animals
Pdgfrβ-Cre+ line [27] and laminin γ1 floxed (F/F) trans-
genic mice [28] were crossed to generate laminin-deficient
PKO (F/F:Pdgfrβ-Cre+) mice. These mice were further
crossed with Nestin-GFP mice [29, 30] to generate control
(F/F:Nestin-GFP) and PKO (F/F:Pdgfrβ-Cre+:Nestin-GFP)
mice under Nestin-GFP background. All mice used in this
study were in a C57BL/6-FVB-BALB/cBy mixed back-
ground. Both males and females were used in this study.
All mice were maintained in the animal facility at Univer-
sity of Minnesota with free access to water and food.
Muscle dissection and preparation
Mice were anesthetized and hindlimb muscles were
carefully dissected and minced with scissors and blades.
The minced muscle fragments were incubated with 0.2%
(w/v) type-2 collagenase (Worthington, LS004176) in
DMEM at 37 °C for 2 h with shaking, followed by 3 ×
15 min incubations with 0.25% trypsin/EDTA at 37 °C.
After trituration and centrifugation at 1500 rpm for
6 min, the supernatant was discarded and the pellet re-
suspended in RBC lysis buffer. After centrifugation, the
pellet was resuspended in DMEM+ 10% FBS and passed
through a 40-μm cell strainer to remove aggregates. The
resulting single cell solution was centrifuged again at
1500 rpm for 6 min and resuspended in sorting buffer
(20 mM HEPES pH 7.0, 1 mM EDTA, 1% BSA in 1 ×
Ca/Mg2+-free PBS pH 7.0). The cells were then stained
with different antibodies and subjected to FACS sorting.
Cell sorting
Type I and type II pericytes were isolated from wild-type
(WT) and PKO mice by FACS as described previously
with minor modifications [9, 10, 14]. In brief, the single
cell solution was stained with PDGFRβ-PE (eBioscience,
12-1402) on ice for 30 min. After extensive wash, DAPI
was added, and PE+GFP− (type I) and PE+GFP+ (type II)
cells were sorted using the Sony SH800 sorter. Forward
and back scatters (FSC and BSC) and DAPI were used
to set a primary gate to exclude dead cells and small
debris. Fluorescence minus one (FMO) control for PE
was used to set the PDGFRβ-PE gating boundary. Cells
dissociated from C57BL/6 mice (not labeled with
Nestin-GFP) were used to set the Nestin-GFP gating
boundary. The cells were sorted into culturing medium
for in vitro experiments.
Cell culture
FACS-isolated type I and type II pericytes were grown in
pericyte medium/growth medium (ScienCell, 1201), myo-
genic differentiation medium (DMEM with 2% horse
serum and 1% penicillin/streptomycin), or adipogenic dif-
ferentiation medium (MesenCult™ Basal Medium supple-
mented with Adipogenic Stimulatory Supplement,
STEMCELL, 05501 and 05503) at 37 °C with 5% CO2.
Medium was changed every 2–3 days until analysis.
In vitro proliferation assay
Proliferation was examined using the Click-iT Plus EdU
Alexa Fluor 594 Imaging Kit (Life Technologies,
C10639). Freshly isolated type I and type II pericytes
were plated in uncoated or laminin-111 (Invitrogen,
23017-015, 5 μg/ml)-coated 24-well plates in pericyte
medium. Two days after plating, Edu (8 μM) was added
to the cells. After 24 h, the cells were fixed and Edu in-
corporation was analyzed according to the manufac-
turer’s instructions. For quantification, the percentage of
Edu+ nuclei among all nuclei in one field was calculated.
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At least eight random fields per sample and five samples
were used for quantification.
In vitro adipogenic differentiation assay
Adipogenic differentiation was induced using adipogenic
differentiation medium. Briefly, freshly isolated type I and
type II pericytes were plated in uncoated or laminin-111
(5 μg/ml)-coated 24-well plates in pericyte medium. After
4 days, pericyte medium was replaced with adipogenic dif-
ferentiation medium containing saline or laminin-111
(5 μg/ml). After 8 or 14 days, the cells were fixed and sub-
jected to perilipin immunostaining, followed by Oil Red
O/hematoxylin staining. Mean perilipin intensity per field
was used to quantify the extent of adipogenesis. At least
eight random fields per sample and four samples were
used for quantification.
In vitro myogenic differentiation assay
Myogenic differentiation was induced using myogenic dif-
ferentiation medium. Briefly, freshly isolated type I and
type II pericytes were plated in uncoated or laminin-111
(5 μg/ml)-coated 24-well plates in pericyte medium. After
4 days, pericyte medium was replaced with myogenic dif-
ferentiation medium containing saline or laminin-111
(5 μg/ml). After 14 days, the cells were fixed and subjected
to S-Myosin (DSHB, MF20, 1:100) immunostaining. Mean
S-Myosin intensity per field was used to quantify the ex-
tent of myogenesis. At least eight random fields per sam-
ple and four samples were used for quantification.
Immunohistochemistry and immunocytochemistry
Transverse muscle sections (10-μm thick) were cut using a
cryostat. Sections of the muscles from one-third and two-
thirds along the anterior/posterior axis were collected.
Muscle sections or sorted cells were immunostained with
anti-laminin γ1 (Abcam, AB3297, 1:200; NeoMarkers, RT-
795-P0, 1:100), anti-PDGFRβ (eBioscience, 14-1402, 1:100),
anti-S-Myosin (DSHB, MF-20, 1:100), anti-perilipin (Sigma,
P1998, 1:500), anti-phospho-histone H3 (Millipore, 06-570,
1:500), or anti-Ki67 (Millipore, AB9260, 1:1000) antibodies
overnight at 4 °C, followed by fluorescent secondary
antibodies (Invitrogen) for 1 h at room temperature.
After mounting, sections were examined and photo-
graphed with a LSM 710 confocal microscopy. For
immunohistochemistry, five random fields from each
section, two sections (one-third and two-thirds along
the anterior/posterior axis) per sample, and five ani-
mals per condition were used for quantification. For
immunocytochemistry, eight random fields from each
experiment and four to five independent sorts/experiments
were used for quantification.
Histology
Oil Red O staining and hematoxylin staining were per-
formed after immunocytochemistry, according to stand-
ard protocols. For Oil Red O staining, after the last step
of perilipin immunocytochemistry, sections were washed
in PBS and afterwards rinsed in 60% isopropanol. After
incubating in Oil Red O (Sigma, O1391) working solu-
tion for 15 min, sections were rinsed in 60% isopropanol
and water. Then, the sections were either mounted in
mounting medium with DAPI (Vector Lab, H-1200) or
stained in hematoxylin (Fisher Scientific, SH30-500D)
for 2 min and then mounted in mounting medium (Vec-
tor Lab, H-1000). The percentage of Oil Red O+ area in
each field was used to quantify the extent of adipogene-
sis. At least eight random fields per sample and four
samples were used for quantification.
Quantitative RT-PCR
RNA isolation was performed using Trizol reagent (Invitro-
gen), followed by RNeasy mini kits (Qiagen). RNA concen-
tration was quantified using a ND1000 spectrophotometer
(Nanodrop). Reverse transcription was performed using
SuperScript III First-Strand Synthesis System (Invitrogen).
Gene expression analysis was performed using SYBR Green
PCR Master Mix (Qiagen) on a LightCycler 480 system
(Roche). The qRT-PCR data were quantified using the com-
parative Ct method [31, 32]. Specifically, the Ct values for
gene of interest (GOI) and the internal controls (IC) in WT
and PKO samples were obtained. The relative expression
change of GOI in PKO pericytes compared with WT
pericytes is calculated using this equation: fold change =
2–ΔΔCt = [(Ct-GOI – Ct-IC)PKO – (Ct-GOI – Ct-IC)wildtype].
Each sample was performed in duplicate, and four inde-
pendent/biological replicates were used for quantification.


























Cells were lysed with RIPA buffer (50 mM Tris pH 7.4, 1%
NP-40, 0.5% Na-deoxycholate, 1% SDS, 150 mM NaCl,
2 mM EDTA, 1 × protease inhibitor cocktail, and 1 ×
phosphatase inhibitor cocktail). Total protein levels were
determined using the Bio-Rad protein assay kit, and equal
amounts of proteins were loaded and separated on SDS-
PAGE. After transferring to PVDF membrane (Millipore),
proteins were detected using a standard immune-blotting
technique. The following primary antibodies were used:
anti-Pax7 (Aviva Systems Biology, ARP32742, 1:400),
anti-Myf5 (Santa Cruz, sc-302, 1:200), anti-Myogenin
(BD Biosciences, 556358, 1:250), anti-phospho-ERK1/2
(Cell Signaling, 4370, 1:1000), anti-ERK1/2 (Cell Signal-
ing, 9107, 1:1000), anti-phospho-p38 (Cell Signaling,
9216, 1:1000), anti-p38 (Cell Signaling, 9212, 1:1000),
anti-integrin α7 (Calbiochem, ST1637, 1:500), anti-
gpihbp1 (Thermo Scientific, PA1-16976, 1:250), anti-
GAPDH (Abcam, ab9484, 1:1000), and anti-β-actin
(Sigma, A5441, 1:2000). Target proteins were visualized
using SuperSignal West Pico Chemiluminescent Sub-
strate (Pierce). The density of target protein bands was
quantified using NIH ImageJ software. The expression
of phospho-ERK1/2 and phospho-p38 was normalized
to ERK1/2 and p38, respectively. The expression of all
other proteins was normalized to GAPDH and/or β-
actin.
ELISA
The levels of BMP-2 and BMP-4 proteins synthesized by
type I pericytes were determined by ELISA. Briefly, WT
and PKO type I pericytes were plated in 24-well plates
in the absence or presence of exogenous laminin-111
(5 μg/ml). The conditioned medium and cell lysates
were collected after adipogenic differentiation for 8 days.
BMP-2 and BMP-4 levels were determined by ELISA ac-
cording to the manufacturer’s instructions (ls-f10947
and ls-f13543, LifeSpan Biosciences). BMP-2 and BMP-4
expression was normalized to total protein level.
Statistics
Results are shown as mean ± SD. Student’s t test per-
formed by SPSS Statistics was used to analyze differences
between two groups (genotypes). Two-way ANOVA in
SPSS Statistics was used for comparisons involving two
factors (genotypes and treatments).
Results
Laminin is abrogated in both type I and type II pericytes
in PKO mice
In a previous study [21], we generated a mouse line
(PKO) with laminin deficiency in pericytes by crossing
the laminin γ1flox/flox (F/F) mice [28] with the Pdgfrβ-
Cre+ transgenic line [27]. To investigate if laminin differ-
entially regulates the proliferation and differentiation of
type I and type II pericytes, we crossed these mice with
Nestin-GFP transgenic line [29, 30] to generate control
(WT) and PKO mice under Nestin-GFP background.
Consistent with previous reports [14, 22, 23], both type I
(PDGFRβ+Nestin−) and type II (PDGFRβ+Nestin+) peri-
cytes were observed in skeletal muscles from WT mice
(Fig. 1a). Both cell types were located in the interstitial
space and expressed laminin (Fig. 1a). Consistent with
our previous finding [21], laminin expression was signifi-
cantly reduced and PDGFRβ expression increased in
PKO muscles (Fig. 1a). Interestingly, GFP+ cells were
also increased in PKO muscles, and most, if not all, GFP
+ cells expressed PDGFRβ (Fig. 1a). Although no differ-
ence in type I pericyte number was observed (Fig. 1b),
quantification revealed significantly more type II peri-
cytes in PKO mice, compared to WT controls (Fig. 1c),
indicating that loss of laminin preferably enhances type
II pericyte number in vivo.
In addition, laminin γ1 expression was absent in
both PDGFRβ+Nestin− and PDGFRβ+Nestin+ cells in
PKO muscles (Fig. 1a), suggesting that laminin ex-
pression is diminished in both type I and type II peri-
cytes in PKO mice. To further examine laminin
expression in type I and type II pericytes, we isolated
these cells from WT and PKO muscles by FACS
using a well-established protocol [9, 10, 14, 21]
(Fig. 2a). FMO control for PDGFRβ was used to set
its gating (Fig. 2b and c). Sorted PDGFRβ+ cells were
further separated based on GFP expression, and
PDGFRβ+GFP− and PDGFRβ+GFP+ populations were
defined as type I and type II pericytes, respectively
(Fig. 2d). Representative dot plots for PDGFRβ and GFP
are shown in Additional file 1 (Figure S1). The purity of
sorted pericytes was examined by immunocytochemistry
against PDGFRβ and NG2, and found to be higher than
95%. Consistent with in vivo studies, laminin γ1 expres-
sion was detected in both type I and type II pericytes iso-
lated from WT muscles, but was absent in both cell types
from PKO muscles (Fig. 2e and f). Quantification
showed that almost all WT pericytes (both type I and
type II) examined in five independent experiments
expressed laminin, while more than 95% of PKO peri-
cytes (both type I and type II) failed to express laminin
(Fig. 2g and h). These data again suggest that laminin
expression is abrogated in both type I and type II peri-
cytes in PKO mice.
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Loss of laminin preferentially induces type II pericyte
proliferation in vivo
In a previous study, we reported increased proliferation
of laminin-deficient pericytes [21]. To investigate if the
proliferation of type I and/or type II pericytes is regu-
lated by laminin, we first performed in vitro proliferation
assay. Type I and type II pericytes were isolated from
WT and PKO mice by FACS as described above and
their proliferation was examined by Edu incorporation
assay 2 days post-isolation (Fig. 3a). Dramatically in-
creased Edu+ cells were observed in PKO type I peri-
cytes, compared to WT controls (Fig. 3b). Statistical
analysis showed that there was a significant difference in
the percentage of Edu+ cells between WT and PKO type
I pericytes (Fig. 3c). Similar result was found for type II
pericytes (Fig. 3d and e), suggesting that laminin nega-
tively regulates the proliferation of both type I and type
II pericytes in vitro. Additionally, exogenous laminin was
able to substantially decrease the proliferation rate of
both type I (Fig. 3b and c) and type II (Fig. 3d and e)
PKO pericytes without affecting that of WT pericytes,
indicating a reversible role of laminin in the proliferation
of both type I and type II pericytes. In addition to Edu,
an S-phase-specific marker [33], we also examined pro-
liferation using phospho-Histone H3 (pH3), an M-
phase-specific marker [34–36]. Similar results were ob-
served; specifically, a higher percentage of pH3+ cells
was found in PKO pericytes (both type I and type II),
and exogenous laminin substantially reduced their pro-
liferation to baseline levels (Additional file 1: Figure S2),
again suggesting that laminin inhibits the proliferation
of both type I and type II pericytes in vitro.
Next, we further examined the proliferation of peri-
cytes in vivo by immunohistochemistry. Consistent with
previous data [21], few proliferating (Ki67+) pericytes
were observed in WT muscles (Fig. 3f ). In PKO muscles,
on the contrary, a large number of Ki67+ cells were
identified (Fig. 3f ). Surprisingly, these Ki67+ proliferating
cells expressed both PDGFRβ and GFP (Fig. 3f ). We
then quantified the number of proliferating type I (Ki67
+PDGFRβ+GFP−) and type II (Ki67+PDGFRβ+GFP+)
pericytes in WT and PKO muscles. Although a compar-
able amount of proliferating type I pericytes was ob-
served in WT and PKO mice (Fig. 3g), significantly more
proliferating type II pericytes were detected in PKO
muscles (Fig. 3h), suggesting that loss of laminin prefer-
entially induces proliferation of type II pericytes in vivo.
These data are consistent with the reported myogenic
function of type II pericytes [14] and muscular dys-
trophic phenotype of the PKO mice [21].
Accumulating evidence suggests that ERK and p38
MAPK pathways play important roles in the proliferation
and differentiation of various mammalian cells [37–39].
To determine if these pathways are involved in loss-of-
laminin-induced proliferation of pericytes, we examined
the activation/phosphorylation of ERK1/2 and p38. Con-
sistent with previous reports demonstrating critical roles
of the ERK pathway in pericyte proliferation [40, 41], we
found high levels of phosphorylated ERK1/2 in both type I
and type II pericytes (Fig. 4), although no significant dif-
ferences in ERK1/2 activation were observed between WT
and PKO pericytes (both type I and type II) (Fig. 4). These
data suggest that the ERK pathway regulates pericyte pro-
liferation, but is not responsible for the enhanced
Fig. 1 Both type I and type II pericytes are found in skeletal muscles. a Immunohistochemical analysis of PDGFRβ (red), GFP (green), and laminin
γ1 (magenta) expression in wild-type (WT) controls and laminin γ1flox/flox:Pdgfrβ-Cre+(PKO) skeletal muscles. b and c Quantification of type I (b)
and type II (c) pericyte number in WT and PKO muscles. n = 5. Data are shown as mean ± SD. **p < 0.01 versus WT. Scale bar = 25 μm
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Fig. 2 Laminin γ1 expression is abrogated in both type I and type II pericytes isolated from laminin γ1flox/flox:Pdgfrβ-Cre+(PKO) mice. a Diagram of
type I and type II pericyte isolation procedure. b Representative plot of PDGFRβ-FMO control. c, d Representative plots showing sorting gates for
PDGFRβ (c) and type I and type II pericytes (d). e Immunocytochemical analysis of laminin γ1 (red) expression in type I pericytes isolated from
wild-type (WT) and PKO muscles. f Immunocytochemical analysis of laminin γ1 (red) and GFP (green) expression in type II pericytes isolated from
WT and PKO muscles. g, h Quantitative data demonstrating the percentage of laminin-positive cells in type I (g) and type II (h) pericytes sorted
from WT and PKO mice. n = 5. Data are shown as mean ± SD. ***p < 0.001 versus WT. Scale bars = 50 μm
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Fig. 3 Laminin negatively regulates the proliferation of type I and type II pericytes. a Diagram of experimental design for Edu incorporation assay. b
Immunocytochemical analysis of Edu (red) in type I pericytes isolated from wild-type (WT) and laminin γ1flox/flox:Pdgfrβ-Cre+(PKO) mice in the presence
of saline (Sal) or laminin-111 (Ln). c Quantification of Edu incorporation in type I pericytes. n = 5. d Immunocytochemical analysis of Edu (red)
in type II pericytes isolated from WT and PKO mice in the presence of Sal or Ln. e Quantification of Edu incorporation in type II pericytes.
n = 5. f Immunohistochemical analysis of PDGFRβ (red), GFP (green), and Ki67 (magenta) expression in WT and PKO muscles. g, h Quantification of
proliferating type I (g) and type II (h) pericyte number in WT and PKO mice. n = 5. Data are shown as mean ± SD. **p < 0.01 versus WT + Sal or WT; ##p
< 0.01 versus PKO + Sal. Scale bars= 100 μm in b and d, and 25 μm in f
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proliferation of PKO pericytes. Additionally, we also ex-
amined the activation of p38. Negligible levels of phos-
phorylated p38 were detected in both type I and type II
pericytes independent of their genotypes (WT vs. PKO;
data not shown), suggesting that p38 may not be involved
in the proliferation of type I and type II pericytes.
Laminin inhibits adipogenesis of type I pericytes
Accumulating evidence suggests that type I rather than
type II pericytes are adipogenic [14, 23, 25]. To investi-
gate the role of laminin in pericyte adipogenesis, we iso-
lated type I and type II pericytes from WT and PKO
muscles and examined their adipogenic differentiation in
vitro (Fig. 5a). After 8 days in adipogenic medium, few
WT type I pericytes expressed the adipocyte marker
perilipin or were stained by Oil Red O, a dye that specif-
ically labels lipids in adipocytes (Fig. 5b). PKO type I
pericytes, however, showed features of mature adipocytes
at both the morphological and biochemical levels. Cells
with typical adipocyte morphology (large cells with mul-
tiple vacuoles) that were positive for perilipin and Oil
Red O were observed (Fig. 5b). Quantifications revealed
significantly higher levels of perilipin intensity (Fig. 5c)
and Oil Red O+ area (Fig. 5d) in PKO type I pericytes,
suggesting that laminin inhibits the adipogenic differen-
tiation of type I pericytes. Furthermore, we found that
the adipogenic differentiation of PKO type I pericytes
was dramatically diminished in the presence of exogen-
ous laminin (Fig. 5b–d), suggesting an anti-adipogenic
potential of laminin. These data are consistent with
previous studies demonstrating anti-adipogenic and
beneficial roles of exogenous laminin in muscular dys-
trophy [21, 42–45]. To explore the molecular mechan-
ism underlying the inhibitory effect of laminin in the
adipogenesis of type I pericytes, we first examined the
expression of gpihbp1, which has been shown to be in-
volved in pericyte adipogenesis [21]. A significantly
lower level of gpihbp1 was found in PKO type I peri-
cytes, and exogenous laminin was able to increase
gpihbp1 expression in type I PKO pericytes (Fig. 6a),
suggesting that gpihbp1 may regulate the adipogenesis
of type I pericytes. Next, we further examined the ex-
pression of various adipogenic factors, including C/
EBPα, C/EBPβ, C/EBPδ, KROX20, KLF5, and FABP4, in
type I pericytes by quantitative RT-PCR. Compared to
WT type I pericytes, PKO type I pericytes demonstrated
a dramatic (four- to six-fold) increase in the expression
of C/EBPβ, KROX20, and KLF5, and a slight decrease of
C/EBPα 4 days after adipogenic differentiation (Fig. 5e).
These data suggest that laminin negatively regulates adi-
pogenesis of type I pericytes via inhibiting the expression
of C/EBPβ, KROX20, and KLF5.
Accumulating evidence shows that BMP-2 and BMP-4
promote adipogenic differentiation of various types of
progenitor/stem cells, including mesenchymal precursor
cells [46–50]. To investigate if loss-of-laminin-induced
adipogenic differentiation of type I pericytes is driven by
BMP proteins, we examined BMP-2 and BMP-4 levels
from type I pericytes 8 days after adipogenic differenti-
ation. Minimal levels of BMP-2 and BMP-4 were de-
tected in conditioned medium independent of genotypes
(WT vs. PKO) and environment (with vs. without ex-
ogenous laminin) (Fig. 6c), suggesting that either these
proteins were not secreted by type I pericytes or were mo-
bilized to cell surface after secretion. Thus, we further ex-
amined BMP-2 and BMP-4 levels in cell lysates from type
I pericytes. Compared to WT cells, PKO type I pericytes
expressed significantly higher levels of BMP-2 and BMP-4
(Fig. 6d). It should be noted, however, that the absolute
level of BMP-2 is substantially higher than that of BMP-4
(Fig. 6d), suggesting that BMP-2 may play a more import-
ant role than BMP-4. In addition, exogenous laminin
slightly reduced BMP-2 expression in type I PKO, al-
though this change was not statistically significant
(Fig. 6d). Laminin treatment also failed to affect BMP-4
expression in type I PKO pericytes (Fig. 6d). Together,
these results suggest that both BMP proteins, especially
BMP-2, may mediate loss-of-laminin-induced adipogenic
differentiation of type I pericytes.
In sharp contrast to type I pericytes, type II pericytes
failed to show signs of adipogenesis after 8 days in adipo-
genic medium (data not shown). To determine if this is
due to a relatively short differentiation time, we allowed
type II pericytes to differentiate in adipogenic condition
Fig. 4 ERK1/2 activation is not responsible for the enhanced
proliferation of PKO pericytes. a Western blots and quantification of
phosphorylated ERK1/2 (p-ERK1/2) expression in wild-type (WT) and
laminin γ1flox/flox:Pdgfrβ-Cre+(PKO) type I pericytes. Total ERK1/2
(t-ERK1/2) was used as a loading control. n = 3. b Western blots and
quantification of p-ERK1/2 expression in WT and PKO type II pericytes.
t-ERK1/2 was used as a loading control. n = 3. Data are shown
as mean ± SD
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Fig. 5 (See legend on next page.)
Gautam et al. Stem Cell Research & Therapy  (2017) 8:28 Page 9 of 16
for up to 14 days (Fig. 5f ). Neither perilipin expression
(Fig. 5g and h) nor Oil Red O signal (Fig. 5g and i) was
observed in type II pericytes, independent of their ge-
notypes (WT vs. PKO). In addition, the same results
were observed in the presence of exogenous laminin
(Fig. 5g–i). Consistent with these results, quantitative
RT-PCR failed to detect any adipogenic factors de-
scribed above in type II pericytes (Fig. 5j). Altogether,
these data strongly suggest that type II pericytes are not
adipogenic.
Laminin is indispensable for myogenesis of type II
pericytes
It has been shown that type II, but not type I, pericytes
have myogenic potential and are able to differentiate
into myogenic cells to repair muscle injury [14, 23, 25].
To determine the role of laminin in pericyte myogenesis,
we isolated type I and type II pericytes from WT and
PKO muscles using FACS, as described above, and ex-
amined their myogenic ability in vitro (Fig. 7a). Consist-
ent with previous reports that type II rather than type I
(See figure on previous page.)
Fig. 5 Laminin inhibits adipogenic differentiation of type I pericytes. a Diagram of experimental design for adipogenic differentiation of type I
pericytes. b Immunocytochemical analysis of perilipin (green) and Oil red O (red) staining in wild-type (WT) and laminin γ1flox/flox:Pdgfrβ-Cre+(PKO) type I
pericytes in the presence of saline (Sal) or laminin-111 (Ln). c Quantification of perilipin (green) expression in type I pericytes after adipogenic differentiation.
n= 4. d Percentage of Oil Red O+ (red) area in type I pericytes after adipogenic differentiation. n= 4. e Quantitative RT-PCR analyses of C/EBPα, C/EBPβ, C/
EBPδ, KROX20, KLF5, and FABP4 expression in type I pericytes 4 days after adipogenic differentiation. n= 4. f Diagram of experimental design for long-term
adipogenic differentiation of type II pericytes. g Immunocytochemical analysis of perilipin (magenta) and Oil red O (red)/hematoxylin (brown) staining in
WT and PKO type II pericytes in the presence of sal or Ln. h Quantification of perilipin (magenta) expression in type II pericytes after adipogenic differenti-
ation. n= 4. i Percentage of Oil Red O+ (red) area in type II pericytes. n= 4. j Quantitative RT-PCR analyses of C/EBPα, C/EBPβ, C/EBPδ, KROX20, KLF5, and
FABP4 expression in type II pericytes 4 days after adipogenic differentiation. n= 4. Data are shown as mean ± SD. *p< 0.05, **p< 0.01 versus WT or WT +
Sal; ##p< 0.01 versus PKO+ Sal. Scale bars= 100 μm
Fig. 6 Gpihbp1 and BMP-2/4 expression in subpopulations of pericytes. a Western blots and quantification of gpihbp1 expression in wild-type
(WT) and laminin γ1flox/flox:Pdgfrβ-Cre+(PKO) type I pericytes in the presence of saline (Sal) or laminin-111 (Ln). Actin was used as a loading control.
n = 4. b Western blots and quantification of gpihbp1 expression in WT and PKO type II pericytes in the presence of Sal or Ln. Actin was used as a
loading control. n = 4. c ELISA analyses of BMP-2 and BMP-4 levels in conditioned medium from type I pericytes after adipogenic differentiation
for 8 days. n = 3. d ELISA analyses of BMP-2 and BMP-4 levels in cell lysates from type I pericytes after adipogenic differentiation for 8 days. n = 3.
Data are shown as mean ± SD. **p < 0.01 versus WT + Sal; #p < 0.05, ##p < 0.01 versus PKO + Sal
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pericytes are myogenic [14, 23, 25], we failed to detect
sarcomere myosin (S-Myosin), a marker for mature myo-
tubes/myofibers, in type I pericytes after 14 days in myo-
genic medium regardless of their genotypes (WT vs. PKO)
or environment (with vs. without exogenous laminin)
(Fig. 7b). Quantification from four independent experi-
ments revealed negligible levels of S-Myosin expression in
type I pericytes (Fig. 7c). Similarly, quantitative RT-PCR
failed to detect any myogenic factors, including Pax7,
MyoD, Myf5, Mrf4, Myog, and S-Myosin, in type I peri-
cytes 4 days after myogenic differentiation (Fig. 7d). These
data strongly indicate that type I pericytes are unable to
undergo myogenic differentiation.
Next, we performed in vitro myogenic assay using type
II pericytes isolated from WT and PKO muscles. After
14 days in myogenic medium, type II pericytes isolated
from WT mice aggregated together, forming myotubes
that were S-Myosin-positive (Fig. 7e). Type II pericytes
isolated from PKO mice, on the other hand, failed to
express S-Myosin or form myotube-like structures after
differentiation for 14 days (Fig. 7e). Interestingly,
exogenous laminin successfully induced the formation of
Fig. 7 Laminin promotes myogenic differentiation of type II pericytes. a Diagram of experimental design for myogenic differentiation.
b Immunocytochemical analysis of S-Myosin (red) in wild-type (WT) and laminin γ1flox/flox:Pdgfrβ-Cre+(PKO) type I pericytes in the presence of saline
(Sal) or laminin-111 (Ln). c Quantification of S-Myosin (red) expression in type I pericytes after myogenic differentiation. n = 4. d Quantitative RT-PCR
analyses of Pax7, MyoD, Myf5, Mrf4, myogenin (Myog), and S-Myosin expression in type I pericytes 4 days after myogenic differentiation. n = 4.
e Immunocytochemical analysis of S-Myosin (red) in WT and PKO type II pericytes in the presence of sal or Ln. f Quantification of S-Myosin (red)
expression in type II pericytes after myogenic differentiation. n = 4. **p < 0.01 versus WT+ Sal. g Quantitative RT-PCR analyses of Pax7, MyoD, Myf5,
Mrf4, Myog, and S-Myosin expression in type II pericytes 4 days after myogenic differentiation. n = 4. h Western blots and quantification of Pax7, Myf5,
and Myog expression in WT and PKO type II pericytes 7 days after myogenic differentiation. GAPDH was used as a loading control. n = 4–5. Data are
shown as mean ± SD. #p < 0.05 versus PKO + Sal; *p < 0.05, **p < 0.01, ***p < 0.001 versus WT. Scale bars= 100 μm in b and 50 μm in d
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S-Myosin+ myotubes in PKO type II pericytes without
affecting WT type II pericytes (Fig. 7e). Quantification
revealed a significant reduction of S-Myosin expression
in PKO type II pericytes compared to WT cells, and a
substantial increase of S-Myosin expression in PKO type
II pericytes treated with exogenous laminin compared to
those treated with saline (Fig. 7f ). In addition, we also
examined the expression of Myogenin (Myog), a key
transcription factor indispensable for myogenesis.
Compared to WT type II pericytes, PKO type II peri-
cytes demonstrated significantly lower levels of Myog
(Additional file 1: Figure S3). Additionally, exogenous
laminin successfully enhanced the expression of Myog in
PKO type II pericytes without affecting that in WT cells
(Additional file 1: Figure S3). These results suggest that
laminin is indispensable for the myogenic differentiation
of type II pericytes.
To explore the molecular mechanism underlying the
role of laminin in the myogenesis of type II pericytes, we
first examined the expression of gpihbp1, which has
been shown to regulate pericyte myogenesis [21]. Com-
pared to WT type II pericytes, PKO type II pericytes
showed reduced expression of gpihbp1 (Fig. 6b). Add-
itionally, exogenous laminin was able to increase
gpihbp1 expression in PKO type II pericytes (Fig. 6b),
suggesting that myogenesis of type II pericytes may be
mediated by gpihbp1. Next, we examined the expression
of various myogenic factors in type II pericytes by quan-
titative RT-PCR. Compared to WT controls, PKO type II
pericytes demonstrated a significant reduction in the ex-
pression of Pax7, MyoD, Myf5, and Mrf4 4 days after
myogenic differentiation (Fig. 7g). In addition, we further
examined the expression of Pax7, Myf5, and Myog in
type II pericytes at protein level 7 days after myogenic
differentiation. Western blot analyses revealed a 30%
and 80% reduction of Pax7 and Myf5 in PKO type II
pericytes, respectively, compared to WT controls
(Fig. 7h). Although Myog mRNA was not altered at
4 days after myogenic differentiation (Fig. 7g), its protein
level was dramatically reduced in PKO type II pericytes
by 7 (Fig. 7h) and 14 (Additional file 1: Figure S3) days
after myogenic differentiation. Furthermore, we also ex-
amined the activation of the p38 MAPK pathway, which
plays a crucial role in the myogenesis of satellite cells
and/or myoblasts [51–55]. Negligible levels of phosphor-
ylated p38 were detected in type II pericytes independ-
ent of their genotypes (WT vs. PKO; data not shown),
suggesting that the p38 MAPK pathway plays a minimal
role in myogenic differentiation of type II pericytes. To-
gether, these data suggest that: (1) laminin induces myo-
genesis of type II pericytes via activating various myogenic
transcription factors; and (2) laminin is involved in the dif-
ferentiation of pericytes into Pax7+, Myf5+, and Myog+
myogenic cells during myogenesis, which is consistent with
previous studies showing that muscle regeneration fails
when Pax7 expression is genetically ablated [8, 56, 57].
It has been shown that integrin α7 (ITGA7), a molecu-
lar marker for myoblasts, functions as a laminin recep-
tor. To examine whether the differences in myogenic
differentiation between type I and type II pericytes in
the presence or absence of exogenous laminin are due to
abnormal expression of ITGA7, we performed Western
blot analysis. Consistent with a previous study reporting
ITGA7 mRNA transcript in pericytes/MSCs [58], ITGA7
protein (120 kDa) was detected in both type I and type
II pericytes (Fig. 8). Compared to WT controls, substan-
tially lower levels of ITGA7 were found in PKO pericytes
(both type I and type II) (Fig. 8), suggesting that laminin
Fig. 8 Laminin regulates ITGA7 expression in both type I and type II pericytes. a Western blots and quantification of integrin α7 (ITGA7; 120 kDa)
expression in wild-type (WT) and laminin γ1flox/flox:Pdgfrβ-Cre+(PKO) type I pericytes in the presence of saline (Sal) or laminin-111 (Ln). Actin was
used as a loading control. n = 3. b Western blots and quantification of ITGA7 (120 kDa) expression in WT and PKO type II pericytes in the presence
of Sal or Ln. Actin was used as a loading control. n = 3. Data are shown as mean ± SD. **p < 0.01 versus WT + Sal; #p < 0.05 versus PKO + Sal
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level positively correlates with ITGA7 expression in peri-
cytes. In addition, exogenous laminin dramatically in-
creased ITGA7 expression in PKO pericytes (both type I
and type II) without affecting that in WT pericytes (Fig. 8),
again suggesting that laminin may regulate ITGA7 expres-
sion in pericytes. Since ITGA7 is expressed in both type I
and type II pericytes, it is less likely to be responsible for
their different myogenic potential.
Discussion
Consistent with previous reports [14, 23, 25], we showed
that type I pericytes are adipogenic and type II pericytes
are myogenic under in vitro conditions. We also demon-
strated that loss of laminin increases the proliferation of
both type I and type II pericytes in vitro, but pre-
ferentially induces the proliferation of type II pericytes
in vivo. In addition, lack of laminin also promotes adipo-
genic differentiation of type I pericytes and inhibits myo-
genic differentiation of type II pericytes in vitro. These
results are consistent with: (1) the observation that both
type I and type II pericytes have direct contact with
laminin-rich basement membrane under physiological
conditions; (2) the “inhibitory” effect of laminin on peri-
cyte differentiation in the brain [59]; and (3) our previ-
ous report [21] that loss of laminin in PDGFRβ+
pericytes (both type I and type II) increases their prolif-
eration, promotes their adipogenic differentiation, and
diminishes their myogenic differentiation. Together, our
data suggest that laminin actively but differentially regu-
lates the proliferation and differentiation of type I and
type II pericytes. The mechanism linking laminin and
different responses of type I and type II pericytes, how-
ever, remains not fully understood. Our mechanistic
studies showed that: (1) loss of laminin activates the adi-
pogenic program in type I pericytes by enhancing the
expression of various adipogenic factors, including C/
EBPβ, KROX20, and KLF5; and (2) loss of laminin inac-
tivates the myogenic program in type II pericytes by de-
creasing the expression of almost all myogenic
transcription factors, including Pax7, MyoD, Myf5, Mrf4,
and Myog. These data suggest that the intrinsic differ-
ence between type I and type II pericytes may be respon-
sible for their distinct behaviors to loss of laminin.
Consistent with previous studies [14, 60], adipogenic fac-
tors were detected in type I but not type II pericytes
after adipogenic differentiation, whereas myogenic fac-
tors were found in type II but not type I pericytes after
myogenic differentiation. These results support that type
I and type II pericytes are intrinsically different and have
distinct differentiation programs. Altogether, our data
suggest that laminin differentially regulates the differen-
tiation and fate determination of type I and type II peri-
cytes by acting on distinct transcription factors in these
cells.
It should be noted that Nestin-GFP+ myofibers are not
detected in Nestin-GFP transgenic mice in vivo, although
type II pericytes show myogenic activity in vitro. This may
be due to the following three possibilities. First, type II
pericytes may lose Nestin-GFP expression after myogenic
differentiation, generating GFP-negative myofibers. Sec-
ond, the contribution of pericytes to myogenesis in vivo
may be below the detection level under physiological con-
ditions. Third, pericytes do not have myogenic capability
in vivo, but obtain myogenic potential in vitro. Recently, it
has been shown that transplantation of DsRed-expressing
type II pericytes into injured muscles leads to DsRed-
positive myofibers after 2 weeks [14], suggesting that type
II pericytes are able to undergo myogenic differentiation
in vivo, at least under pathological conditions. Therefore,
we favor the first two possibilities.
In the in vitro proliferation assay, we showed that exogen-
ous laminin failed to decrease the proliferation of WT peri-
cytes. This could be due to the fact that endogenous
laminin produced by WT pericytes is sufficient to inhibit
and maintain the proliferation at baseline. An alternative
explanation is that endogenous pericytic laminin and ex-
ogenous laminin may be different in their compositions
and functions. The exogenous laminin we used in this study
is mouse laminin-111, which is the only commercially avail-
able recombinant laminin of mouse origin. Although
expressed at the embryonic stage, this laminin isoform is
absent in adult skeletal muscles [61–67]. In addition, al-
though the exact laminin isoforms produced by pericytes
are not clear, many other laminin chains, including laminin
α4 and β2, are detected [68]. Ongoing projects in our la-
boratory focus on identifying laminin isoforms synthesized
by pericytes and investigating their biological functions.
The fact that exogenous laminin successfully reversed
the proliferation and differentiation phenotypes of PKO
pericytes suggests that laminin-111 could at least par-
tially compensate for the loss of pericyte-derived laminin
isoforms. This is consistent with previous reports on the
compensatory effects of laminin-111. For example, ex-
pressing laminin α1 is able to improve the general health
(body weight and lifespan) and muscle deficit in laminin
α2-deficient mice [69–74], a widely used congenital mus-
cular dystrophy model [75–77]. Furthermore, recombin-
ant laminin-111 has been shown to improve muscle
pathology and function in various muscular dystrophy
models, including those caused by lack of laminin α2 [42,
44] and laminin γ1 [21]. Additionally, laminin α1, espe-
cially its globular domains, has been shown to partially
compensate for the developmental defect caused by loss
of laminin α5 [78, 79]. Given the diverse biological func-
tions and strong therapeutic potential of laminin-111, it is
not surprising to see that the deficits in proliferation and
differentiation of PKO pericytes can be rescued by ex-
ogenous laminin-111.
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In muscle injury induced by glycerol or BaCl2, both type I
and type II pericytes were reported to expand in vivo [14].
In contrast to that study, we found that type II pericytes
predominantly proliferate in pericytic laminin-deficient
mice. Given that type II pericytes have myogenic capability
[14] and that the pericytic laminin-deficient mutants de-
velop severe muscular dystrophy [21], this finding suggests
that laminin is indispensable for the myogenesis of type II
pericytes. The discrepancy may be explained by either
pericytic laminin only regulates the proliferation of type II
pericytes, or different injury models create different micro-
environments that lead to distinct outcomes. Given that
loss of pericytic laminin enhances the proliferation of both
type I and type II pericytes in vitro, we favor the second
possibility. The exact microenvironment created in PKO
mice and how it induces predominant proliferation of type
II pericytes in vivo, however, remain unclear. Answers to
these questions would allow us to identify subtype-
specific pathways, separate subtype-specific functions,
and hopefully achieve therapeutic potential by manipulating
different subtypes of pericytes.
Conclusions
Laminin predominantly inhibits the proliferation of type II
pericytes in vivo, and negatively and positively regulates
the adipogenic and myogenic differentiation of type I and
type II pericytes, respectively.
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Additional file 1: Figure S1. Representative dot plots for PDGFRβ-PE and
Nestin-GFP in FACS analysis. (a) Representative dot plot for PDGFRβ-FMO
control. (b) Representative dot plot showing sorting gates. Figure S2. Lam-
inin inhibits the proliferation of type I and type II pericytes in vitro. (a) Quan-
tification of pH3+ cell percentage in type I pericytes in the presence of sal or
ln. n = 4. (b) Quantification of pH3+ cell percentage in type II pericytes in the
presence of Sal or Ln. n = 4. Ln laminin-111, Sal saline, WT wildtype. Data are
shown as mean ± SD. **p < 0.01 versus WT + Sal; ##p < 0.01 versus PKO + Sal.
Figure S3. Laminin induces Myogenin expression in type II pericytes after
myogenic differentiation. Western blots and quantification of Myog expres-
sion in WT and PKO type II pericytes after myogenic differentiation. Actin
was used as a loading control. n = 4. Ln laminin-111, Sal saline, WT wildtype.
Data are shown as mean ± SD. **p < 0.01 versus WT + Sal; # p < 0.05 versus
PKO + Sal. (DOCX 17413 kb)
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